You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)推介材料:預測明年增長50%以上
阿思達克 10-21 17:11
藥明生物(02269.HK)今日股價抽高11.6%收225元,成升幅最大藍籌股。根據藥明生物網站的推介材料,昨公司發布一份面向投資者的資料截至10月15日止公司匯報期內共新增72個項目,有23個項目進入後期。

公司於10月至今總未交付訂單達到103億美元(約為798.26億港元)。公司預計明年增長可達50%以上,料受惠新冠疫苗及單抗,並相信於2022年可續保持較高增長。

此外,麥格理發表研究報告指,藥明生物首席執行官昨日舉行了投資者會議,並將今年下半年盈利增長指引由30%升至40%,而2021及2022年的增長指引則由逾40%增至逾50%。(wl/k)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account